Abstract 1279P
Background
Targeted and immune-therapies are currently recommended in early-stage NSCLC. However, biomarker prevalence data are limited in Latin America (LATAM). EARLY-EGFR (NCT04742192) determined the frequency of EGFRm in pts with resected stage I-III NSCLC across Asia, Middle East and Africa and LATAM.
Methods
The LATAM subset of this descriptive, observational, real-world study prospectively enrolled consecutive pts with surgically-resected stage IA-IIIB (AJCC 8th edi.) non-squamous NSCLC from Mar 2021-Oct 2022. Primary endpoint was EGFRm prevalence and secondary endpoints were EGFRm subtypes, clinico-demographics and treatment patterns. Association between EGFRm and clinico-demographic factors was assessed by Fisher's exact test with Monte Carlo.
Results
80 pts were enrolled with mean±SD age of 66.5±9.7 yrs; 67.5% females and 57.5% never smokers. All pts had adenocarcinoma. Pathological stage (PS) distribution was PS I 66.3%, PS II 20.0% and PS III 13.8%. Most pts (61.3%) had right lung involvement and 85.0% were pN0. EGFRm prevalence was 39.5% (30/76) with similar rates in males and females (39.1% vs 39.6%; Table). Exon-19 deletions (36.7%) and 21-L858R (30.0%) accounted for two-thirds of mutations. 4 of 11 (36.4%) pts with EGFRm were found to be PD-L1 positive. EGFRm rate in never smokers was significantly higher than in current and former smokers (51.2% vs 24.2%, p=0.017). 76.3% underwent only surgical resection. Of 44 PS IB-IIIB pts, 31.8% received systemic adjuvant therapy (AT), mostly platinum-based chemotherapy. Per logistic regression analysis age ≥60 years had increased odds of EGFRm, while smokers had decreased odds of EGFRm (both p<0.05).
Table: 1279P
EGFRm in the LATAM cohort
Characteristics | N=80, n (%) | Comparison of mutation rate | |||
EGFRm (N=30) | EGFR wild type (N=46) | Mutation Rate (%) | |||
Age (years) | <60 | 21 (26.3) | 05 | 14 | 26.3 |
60-80 | 53 (66.3) | 21 | 31 | 40.4 | |
>80 | 06 (7.5) | 04 | 01 | 80.0 | |
Gender | Female | 54 (67.5) | 21 | 32 | 39.6 |
Male | 26 (32.5) | 09 | 14 | 39.1 | |
Smoking history | Current | 03 (3.8) | 01 | 01 | 50.0 |
Former | 31 (38.8) | 07 | 24 | 22.6 | |
Never | 46 (57.5) | 22 | 21 | 51.2a | |
Family history of lung cancer | No | 72 (90.0) | 28 | 40 | 41.2 |
Yes | 03 (3.8) | 01 | 02 | 33.3 | |
PS (AJCC 8th edi.) | I | 53 (66.3) | 19 | 31 | 38.0 |
II | 16 (20,0) | 07 | 08 | 46.7 | |
III | 11 (13.8) | 04 | 07 | 36.4 |
Note: Four pts failed EGFR test aBy smoking history (current and former vs never; p=0.017) Countries: Argentina, Chile, Colombia, Costa Rica, Dominican Republic, Mexico and Peru
Conclusions
The LATAM subset shows a EGFRm prevalence of 39.5%. Despite ASCO guidelines recommending AT in PS IB-IIIB, only about 32% received it. Our results are important for guiding EGFR testing and informing treatment strategies in LATAM with recent and upcoming approvals of targeted and immune-therapies.
Clinical trial identification
NCT04742192.
Editorial acknowledgement
Medical writing assistance was provided by Prajakta Nachane (M Pharm) of Labcorp Scientific Services & Solutions Pvt. Ltd. funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
E. Amorin: Financial Interests, Institutional, Local PI: Clínica Delgado Auna. H.A. Perroud: Financial Interests, Institutional, Steering Committee Member: Sanatorio de la Mujer. L.G. Hellal: Financial Interests, Institutional, Local PI: Fundación Santa Fé. S.V. Francisco: Financial Interests, Institutional, Local PI: Clínica Santa María. A.P. Guerrero: Financial Interests, Institutional, Local PI: Instituto Nacional del Cáncer Rosa Emilia Sánchez Pérez de Tavares. A. Vasquez: Financial Interests, Institutional, Local PI: Mediadvance. L.F.T. Gallegos, N. Donner, R. Huggenberger: Financial Interests, Institutional, Full or part-time Employment: AstraZeneca. L. Corrales: Financial Interests, Institutional, Local PI: Centro de Investigación y Manejo del Cáncer.
Resources from the same session
1265P - Toripalimab plus chemotherapy as neoadjuvant treatment for resectable stage IIB-IIIB NSCLC (RENAISSANCE study): A single-arm, phase II trial
Presenter: Shi Yan
Session: Poster session 04
1266P - Prediction of lung cancer risk in ground-glass nodules using deep learning from CT images
Presenter: Anil Vachani
Session: Poster session 04
1267P - Enhancing pulmonary nodule diagnosis: A combinatorial model of cfDNA methylation, plasma proteins and LDCT imaging
Presenter: Meng Yang
Session: Poster session 04
1268P - Liquid biopsy and CT-based multi-omics fusion enhances differential diagnosis of early-stage lung adenocarcinoma
Presenter: Yanwei Zhang
Session: Poster session 04
1269P - Machine learning model for predicting lung cancer recurrence after surgical treatment: A retrospective study using NLST and European hospital data
Presenter: Ann Valter
Session: Poster session 04
1272P - Postoperative survival prediction in non-small cell lung cancer patients based on driver genotypes
Presenter: Huiting Wang
Session: Poster session 04
1273P - The prognostic value evaluation of a tissue Comprehensive Genomic Profiling (CGP)-informed personalized MRD detection assay in NSCLC
Presenter: Wei Gao
Session: Poster session 04
1274P - Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer
Presenter: Kyungmi Yang
Session: Poster session 04
1275P - Genomic analysis of lung adenocarcinoma with micropapillary component: Identification of micropapillary-related subtypes and development of a prognostic model
Presenter: Yuechun Lin
Session: Poster session 04